Journal
HEART RHYTHM
Volume 5, Issue 8, Pages 1210-1212Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.hrthm.2008.05.006
Keywords
ventricular fibrillation; torsade de pointes; QT liability; repolarization disturbances; cardiac wavelength
Categories
Ask authors/readers for more resources
Not all drugs that prolong the QT interval are proarrhythmic, and absence of QT prolongation is no guarantee for Lack of proarrhythmia. Thus, QT prolongation is an unreliable predictor of ventricular arrhythmia. Development of drugs based on the absence of QT prolongation may stop development of some of the safest agents (with respect to arrhythmias). Conversely, drug-induced shortening of the QT interval may facilitate reentry, which might have Lethal consequences in vulnerable patients. If QT prolongation and QT shortening must be avoided, then the pharmaceutical industry faces a mission impossible. Cardiac safety is better evaluated in terms of lambda, TRIaD (Triangulation, Reverse use dependence, Instability, and Dispersion), and disturbances of automaticity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available